CEBINA GmbH Press Releases

• Published on December 11, 2024 - 10:40 GMT

  

  CEBINA and Danube BioVentures announce the launch of TAG Therapeutics developing a new approach for telomere pathologies

  VIENNA, AUSTRIA, December 11, 2024 /⁨EINPresswire.com⁩/ -- Danube Labs, a life science acceleration partnership formed by CEBINA GmbH (Central European Biotech Incubator and Accelerator), Evotec SE and the biotech fund Danube BioVentures, announces the …

  Distribution channels: Business & Economy, Companies ...
• Published on September 17, 2024 - 12:00 GMT

  CEBINA and Charles River Laboratories announce strategic collaboration to accelerate neuroscience research

  VIENNA, VIENNA, AUSTRIA, September 17, 2024 /⁨EINPresswire.com⁩/ -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, and Charles River Laboratories International, Inc. (NYSE: CRL), announce today a strategic collaboration within the …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on February 28, 2024 - 10:44 GMT

  CEBINA announces the launch of DanubeNeuro, an acceleration program for innovative neuroscience research

  VIENNA, AUSTRIA, February 28, 2024 /⁨EINPresswire.com⁩/ -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, announces today the launch of the DanubeNeuro program advancing breakthrough innovative academic research projects in the field of …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on December 18, 2023 - 11:52 GMT

  

  Eveliqure initiates clinical safety, immunogenicity trials of vaccine candidate against Shigellosis, ETEC in Bangladesh

  VIENNA, AUSTRIA, December 18, 2023 /⁨EINPresswire.com⁩/ -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, announces the commencement of a Phase 1b clinical trial with ShigETEC, its vaccine candidate against shigellosis and …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on July 4, 2022 - 10:57 GMT

  

  CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

  VIENNA, VIENNA, AUSTRIA, July 4, 2022 /⁨EINPresswire.com⁩/ -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...